Monday 06 March 2017 - Tuesday 07 March 2017
Venue: Cambridge, UK
SELECTBIO is thrilled to announce the continuation of Epigenetics in Drug Discovery for 2017. The event will be one of four tracks within the multi-track conference, Advances in Drug Discovery. Registered delegates will have unrestricted access to all conference tracks and networking opportunities.
Attracting researchers from both academia and industry, EDD will explore the latest opportunities and challenges for epigeneticists looking to discover and develop new molecular entities.
Topics to be addressed include, assays for Methyltranferases and Demethylases, Bromodomain inhibitor discovery, indications beyond cancer, Non-BET Bromodomains and of course updates in Oncology. The agenda is available to view on the website.
If you work in epigenetics research, you will benefit from the expert knowledge of academic and industry leaders who are pushing the boundaries of drug discovery, whilst networking with the technology providers who are enabling them to do so.
Present your research on a poster while attending the meeting. Poster Submission Deadline: 20 February 2017.
Visit the website for up-to-date information, including details of our 3 for 2 offer on registration! Early bird – Register by 3 February 2017.
|Mon, Mar 6th, 2017 Epigenetics in Drug Discovery 2017|
|Wed, Apr 5th, 2017 Chromatin and Epigenetics: from Mechanism to Function|
|Wed, May 3rd, 2017 EMBO Conference: Chromatin and Epigenetics|
|Tue, Jul 11th, 2017 Mendelian randomization in the age of large-scale accessible genomics data|
|Wed, Aug 30th, 2017 EMBO Conference: The Nucleosome: From Atoms to Genomes|
|Wed, Sep 6th, 2017 EMBO Workshop on Histone variants: Molecular functions in health and disease|
|Thu, Sep 7th, 2017 EMBO Conference|
|Thu, Oct 12th, 2017 3rd Annual Epigenetics Discovery Congress|
|Sun, Nov 12th, 2017 EMBO | EMBL Symposium: From Single- to Multiomics: Applications and Challenges in Data Integration|